Linsitinib (OSI-906)

Name: Linsitinib (OSI-906)
Brand: Selleck Chemicals
SKU: S1091
Rating: 5 (91 reviews)

For research use only.

Catalog No.S1091

91 publications

CAS No. 867160-71-2

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Selleck's Linsitinib (OSI-906) has been cited by 91 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7719):499-503

PubMed: 30051890 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):439-452

PubMed: 30205046 ( click the link to review the publication )

Nature, 2016, 24;539(7630):570-574.

PubMed: 27820945 ( click the link to review the publication )

Nat Med, 2014, 20(9):1027-34

PubMed: 25173427 ( click the link to review the publication )

J Invest Dermatol, 2020, 3 pii: S0022-202X(20)31407-X

PubMed: 32376279 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 13;5(1):53

PubMed: 32398667 ( click the link to review the publication )

FASEB J, 2020, 34(4):5363-5388

PubMed: 32067272 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(3):920-926

PubMed: 31871269 ( click the link to review the publication )

Front Endocrinol (Lausanne), 2020, 16;11:219

PubMed: 32373071 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

Acta Pharm Sin B, 2020, 10(1):186-194

PubMed: 31993315 ( click the link to review the publication )

Nat Commun, 2019, 10(1):518

PubMed: 30705270 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2244-2256

PubMed: 30833419 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32668

PubMed: 31490549 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(6):1185-1199

PubMed: 30623207 ( click the link to review the publication )

Cancer Lett, 2019, 456:59-68

PubMed: 31042587 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )
FASEB J, 2019, 33(10):11210-11222

PubMed: 31291762 ( click the link to review the publication )

Cells, 2019, 8(4)

PubMed: 30965609 ( click the link to review the publication )

J Gerontol A Biol Sci Med Sci, 2019, 74(9):1375-1385

PubMed: 30329021 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480400 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

Mediators Inflamm, 2019, 2019:5497467

PubMed: 31467485 ( click the link to review the publication )

Endocr Connect, 2019, 8(6):680-690

PubMed: 31035254 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1777

PubMed: 29725014 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2546

PubMed: 29959327 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1580

PubMed: 30274984 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1574

PubMed: 30279230 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-0372

PubMed: 30397176 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(17):4282-4296

PubMed: 29716918 ( click the link to review the publication )

Biomaterials, 2018, 155:64-79

PubMed: 29169039 ( click the link to review the publication )

Cancer Res, 2018, 78(14):3995-4006

PubMed: 29669759 ( click the link to review the publication )

Cancers (Basel), 2018, 10(9)

PubMed: 30227608 ( click the link to review the publication )

J Mol Cell Biol, 2018, 10(4):331-340

PubMed: 29190376 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2217-2225

PubMed: 30045926 ( click the link to review the publication )

Cell Oncol, 2018, 41(3):283-296

PubMed: 29470830 ( click the link to review the publication )

Endocrinology, 2018, 159(1):285-296

PubMed: 29029116 ( click the link to review the publication )

Front Endocrinol, 2018, 9:178

PubMed: 29731738 ( click the link to review the publication )

Oncotarget, 2018, 9(10):8810-8822

PubMed: 29507656 ( click the link to review the publication )
Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(11):2795-2805

PubMed: 27903677 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1842-1853

PubMed: 28209619 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(4):328-340

PubMed: 27987211 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):705-716

PubMed: 28138037 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):88-101

PubMed: 28062706 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(11):895-903

PubMed: 28696156 ( click the link to review the publication )

Cancer Med, 2017, 6(6):1353-1361

PubMed: 28440057 ( click the link to review the publication )

Biochimie, 2017, 138:62-69

PubMed: 28438671 ( click the link to review the publication )

J Cell Biochem, 2017, 118(7):1774-1781

PubMed: 27987331 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0170083

PubMed: 28076448 ( click the link to review the publication )

Exp Lung Res, 2017, 43(1):29-37

PubMed: 28394654 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103465-103476

PubMed: 29262576 ( click the link to review the publication )

Hepatology, 2017, 66(6):2002-2015

PubMed: 28653763 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(6):481-93

PubMed: 27185872 ( click the link to review the publication )

Front Cell Dev Biol, 2016, 4:114

PubMed: 27800477 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(5):411-22

PubMed: 26785999 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2016, 55(6):779-791

PubMed: 27438786 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Science, 2016, 352(6288):aad3018

PubMed: 27199435 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27511-26

PubMed: 27050276 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(6):1373-82

PubMed: 25609059 ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: ( click the link to review the publication )
J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: 25485727 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(17):2991-3004

PubMed: 26100015 ( click the link to review the publication )

Vascul Pharmacol, 2015, 10.1016/j.vph.2015.04.005

PubMed: 25921925 ( click the link to review the publication )

Med Oncol, 2015, 32(6):577

PubMed: 25956506 ( click the link to review the publication )

Int J Clin Exp Med, 2015, 8(4):6563-7

PubMed: 26131286 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Leukemia, 2014, 28(11):2197-205

PubMed: 24699302 ( click the link to review the publication )

Endocrinology, 2014, 155(6):2102-11

PubMed: 24712877 ( click the link to review the publication )

Pharm Res, 2014, 31(11):3060-72

PubMed: 24906597 ( click the link to review the publication )

Arch Biochem Biophys, 2014, 558C:42-50

PubMed: 24933099 ( click the link to review the publication )

J Cell Biochem, 2014, 115(12):2208-17

PubMed: 25147082 ( click the link to review the publication )

Biometals, 2014, 27(2):317-32

PubMed: 24535192 ( click the link to review the publication )

Blood, 2013, 122(9):1621-33

PubMed: 23863897 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Diabetes, 2013, 62(10):3448-58

PubMed: 23801577 ( click the link to review the publication )

BMC Cancer, 2013, 13:245

PubMed: 23688189 ( click the link to review the publication )

Cancer Cell Biology, 2013, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Cancer Res, 2012, 73(2):834-43

PubMed: 23172312 ( click the link to review the publication )

Cancer Res, 2011, 71(21):6773-84

PubMed: 21908557 ( click the link to review the publication )

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Targets

IGF-1R ^[1] (Cell-free assay)	Insulin Receptor ^[1] (Cell-free assay)	IRR ^[1] (Cell-free assay)
35 nM	75 nM	75 nM

In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A4-Fuk	M4\1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXuWlJKSzVyPUCuNFI5ODZizszN	MoLwV2FPT0WU
KS-1	NFfGS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjmTWM2OD1yLkCzPFM2KM7:TR?=	NELYWJNUSU6JRWK=
TE-11	M2jZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;qTWM2OD1yLkC3PFIzKM7:TR?=	NHP0PZNUSU6JRWK=
EW-1	NUjFTWNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\HbFNpUUN3ME2wMlA5PTh3IN88US=>	M1XxT3NCVkeHUh?=
HMV-II	NFnyR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XL[WlEPTB;MD6wPFg1PiEQvF2=	M132e3NCVkeHUh?=
COLO-205	MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TGdWlEPTB;MD6xNFQ2PCEQvF2=	MUXTRW5ITVJ?
ES1	NF;NS\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7UbVFKSzVyPUCuNVA3QTZizszN	MYrTRW5ITVJ?
GDM-1	MofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlf5TWM2OD1yLkGzOlczKM7:TR?=	NXLZZlk6W0GQR1XS
ML-2	MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrKeoFmUUN3ME2wMlE2QDl4IN88US=>	M163NXNCVkeHUh?=
Saos-2	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnj3TWM2OD1yLkG2OVI3KM7:TR?=	NHn5OHlUSU6JRWK=
NCI-H1355	NXrvbIJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF35TXFKSzVyPUCuNVgyOzVizszN	NFy1TmpUSU6JRWK=
G-401	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\IT252UUN3ME2wMlE5OjNizszN	MlWyV2FPT0WU
EW-16	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7ZR5RKSzVyPUCuNVg4PzdizszN	M1;uPXNCVkeHUh?=
EW-7	M{HvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYH3cmw4UUN3ME2wMlE5QDhzIN88US=>	NVLSeJBbW0GQR1XS
NCI-H727	NYD2SlRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfyTWM2OD1yLkG5O\|k1KM7:TR?=	MnLIV2FPT0WU
LCLC-97TM1	NHLMSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fo[GlEPTB;MD6yNFk2PSEQvF2=	NWDLWXNDW0GQR1XS
NCI-H650	M4fKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTBwMkGzPFQh\|ryP	M{WzTnNCVkeHUh?=
NCI-H2122	MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\vNGdKSzVyPUCuNlMzQTlizszN	MlnlV2FPT0WU
SK-N-DZ	NYK5T4FbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI[xV5ZKSzVyPUCuNlM3QThizszN	MVPTRW5ITVJ?
HT-29	MmH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTBwMkSyOFgh\|ryP	M1LhbHNCVkeHUh?=
LB771-HNC	NUXhcZRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;rTWM2OD1yLkK1PVE2KM7:TR?=	MXzTRW5ITVJ?
HT-144	NEeyfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoWwTWM2OD1yLkK2NVkyKM7:TR?=	NHzzcmdUSU6JRWK=
LAN-6	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33iO2lEPTB;MD6yOlM1QCEQvF2=	M4[w[nNCVkeHUh?=
EW-18	M2HPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfmZYZKSzVyPUCuNlcxODFizszN	NVXMSXJoW0GQR1XS
LS-1034	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NES4d\|BKSzVyPUCuNlcyOzJizszN	MlXIV2FPT0WU
EW-11	NHyy[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fuVWlEPTB;MD6yPFQ{OiEQvF2=	NEPIPWRUSU6JRWK=
SNU-C1	MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPyfYRxUUN3ME2wMlI6OzF\|IN88US=>	MnXOV2FPT0WU
RS4-11	NFeyUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zEemlEPTB;MD6zN\|c2QCEQvF2=	NHLyRmVUSU6JRWK=
ES4	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrtRYJPUUN3ME2wMlQyODN6IN88US=>	NIDPcI5USU6JRWK=
COLO-320-HSR	NXjwcHdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFOwdZhKSzVyPUCuOFE{PjhizszN	NUOzPXl{W0GQR1XS
NB10	M3jMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwNEW0N\|ch\|ryP	M3\aVnNCVkeHUh?=
BFTC-905	NFvJOJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTBwNE[3OVgh\|ryP	NHXpTphUSU6JRWK=
A375	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInoeWNKSzVyPUCuOFc3OTdizszN	NGDvd3dUSU6JRWK=
SJRH30	NXfSe3g5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fqVGlEPTB;MD61NFgzOiEQvF2=	M1P3Z3NCVkeHUh?=
NOS-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm[4TWM2OD1yLkWyNlY4KM7:TR?=	NH30[4hUSU6JRWK=
SIG-M5	MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwNUO1OVch\|ryP	MmTQV2FPT0WU
DOK	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIq2fZVKSzVyPUCuOVU3KM7:TR?=	MlXXV2FPT0WU
NB69	NWn1UVdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzp[VJKSzVyPUCuOVgzPTdizszN	MnjpV2FPT0WU
SK-NEP-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTV[ZdsUUN3ME2wMlYxOjN4IN88US=>	NVW2cZlpW0GQR1XS
SK-MM-2	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwNkW0PVEh\|ryP	M2exTHNCVkeHUh?=
NCI-H358	NFjaN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLzTWM2OD1yLk[3NFgzKM7:TR?=	NULk[GZ5W0GQR1XS
RH-1	NVK0O5ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DxTGlEPTB;MD63OFg2QSEQvF2=	NWLOUmJnW0GQR1XS
NH-12	NEnmZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nqV2lEPTB;MD63OlA1PiEQvF2=	M1X2dHNCVkeHUh?=
TE-12	NGDqU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVz0XmJXUUN3ME2wMlc3PDh4IN88US=>	NXPmXpVtW0GQR1XS
COLO-668	MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmj4TWM2OD1yLki0OlY3KM7:TR?=	NUjrPWtVW0GQR1XS
PANC-08-13	Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkWwTWM2OD1yLki2N\|c4KM7:TR?=	NUf3c2JbW0GQR1XS
HCC2998	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlT6TWM2OD1yLki4NlY{KM7:TR?=	NHW1NHZUSU6JRWK=
ABC-1	MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTBwOUCzOVIh\|ryP	MXfTRW5ITVJ?
ES6	NXfxSnJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDRTHllUUN3ME2wMlkyODZ4IN88US=>	NUP4b3RLW0GQR1XS
SNU-387	NFzZS\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M370O2lEPTB;MD65PVM6OyEQvF2=	NFWyR2NUSU6JRWK=
CMK	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHyTHhpUUN3ME2wMlk6QTJ7IN88US=>	M{\wTHNCVkeHUh?=
SJSA-1	NELOcmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTFwMEO2OVMh\|ryP	MljGV2FPT0WU
SIMA	NUnaT4ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGC2UIdKSzVyPUGuNFY5OjVizszN	NIrqS\|hUSU6JRWK=
ES3	M1LHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3pS4pKSzVyPUGuNVIzQTdizszN	NV;NXIZDW0GQR1XS
IGROV-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTFwMUW0OFQh\|ryP	M1ntNXNCVkeHUh?=
MEL-JUSO	NIW2VWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;KbGVKSzVyPUGuNVU4PTlizszN	M2nKVnNCVkeHUh?=
T84	NUjNXnkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfRXohKSzVyPUGuNlA6OTRizszN	M4LLU3NCVkeHUh?=
CAL-85-1	NX;qVHRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfpRoRKSzVyPUGuNlMyOzhizszN	Mm\xV2FPT0WU
RD	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLvOmF{UUN3ME2xMlI3PDV3IN88US=>	NIK0XmlUSU6JRWK=
TE-8	NGPtXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTFwM{G0OlIh\|ryP	M1zKU3NCVkeHUh?=
L-363	NYr1RmZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTFwM{SyNFgh\|ryP	MlvwV2FPT0WU
EKVX	MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{S1[mlEPTB;MT6zOFU3QCEQvF2=	Ml\uV2FPT0WU
SK-MEL-3	NUHDRnV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV6zRnBZUUN3ME2xMlQ5PTV4IN88US=>	NEHkc\|VUSU6JRWK=
TGBC24TKB	NEG2cnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2juWWlEPTB;MT61NFE6OyEQvF2=	NFzjWnNUSU6JRWK=
NCI-H1770	NH\jOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\CXYNKSzVyPUGuOVEyOTNizszN	NHW2SGVUSU6JRWK=
HuH-7	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TwfGlEPTB;MT62NFA6QCEQvF2=	NVX0W\|E{W0GQR1XS
HL-60	M33x[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTFwNk[5Nlgh\|ryP	MlXGV2FPT0WU
TE-1	NVfGfndPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVWyTJV5UUN3ME2xMlcxQTR3IN88US=>	M3\n[nNCVkeHUh?=
LC-2-ad	M{\sZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTHUWR1UUN3ME2xMlc{QDh5IN88US=>	MYPTRW5ITVJ?
LB647-SCLC	NVTsbZIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTFwN{[1PFMh\|ryP	NWWyPZhkW0GQR1XS
NCI-H2171	NXvp[HhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fhXmlEPTB;MT63O\|cyPiEQvF2=	MV7TRW5ITVJ?
SK-PN-DW	NWq1dGwyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTFwOUGyPVgh\|ryP	MnnKV2FPT0WU
MC-IXC	M2nHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETvbVhKSzVyPUGuPVg6QCEQvF2=	M17CcHNCVkeHUh?=
LS-513	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXGyWmszUUN3ME2yMlA2OzB3IN88US=>	NHfaWXVUSU6JRWK=
EW-3	Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7W[XJtUUN3ME2yMlA6QDR2IN88US=>	MmDUV2FPT0WU
OPM-2	MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\kc3loUUN3ME2yMlExOiEQvF2=	MWHTRW5ITVJ?
LP-1	NVjteJBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HSWmlEPTB;Mj6yOVgxPyEQvF2=	NYryRXYyW0GQR1XS
LU-134-A	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknJTWM2OD1{LkK3O{DPxE1?	M3HEPHNCVkeHUh?=
CP66-MEL	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTJwMkmwNVQh\|ryP	M1nJRnNCVkeHUh?=
HCC1143	NHnuVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkCwTWM2OD1{LkS1N\|Y5KM7:TR?=	MVnTRW5ITVJ?
LOXIMVI	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLGTWM2OD1{Lk[wNlEh\|ryP	NFjOR5FUSU6JRWK=
TE-10	M3K0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvyTWM2OD1{LkewPFM5KM7:TR?=	Mo\IV2FPT0WU
NCI-H1882	NXPVPZluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fBRmlEPTB;Mj63OVIzPyEQvF2=	MkXXV2FPT0WU
CHP-126	NGi0R\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnn3TWM2OD1{Lke2N\|E4KM7:TR?=	MUjTRW5ITVJ?
NCI-H1623	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmCxTWM2OD1{LkmyNFI1KM7:TR?=	MYDTRW5ITVJ?
GB-1	MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXyzfnpsUUN3ME2yMlk{PDB2IN88US=>	NFvodpRUSU6JRWK=
RCC10RGB	NVSxVo9zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTJwOUWyPFEh\|ryP	MmnWV2FPT0WU
NCI-H2141	NEPoToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTJwOU[4PVYh\|ryP	MoXXV2FPT0WU
GI-ME-N	Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7zXI5KSzVyPUOuNFA2PjVizszN	MlnhV2FPT0WU
NCI-H526	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1qxOWlEPTB;Mz6wOFA5PSEQvF2=	NEHGOI5USU6JRWK=
NCI-H747	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\LfWlEPTB;Mz6wOFk6OiEQvF2=	Mor0V2FPT0WU
SNU-423	NGnm[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTNwMkCzNVMh\|ryP	MUPTRW5ITVJ?
A427	MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnuUmNKSzVyPUOuNlU3QTlizszN	M4P5OnNCVkeHUh?=
CAL-12T	MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjQTWM2OD1\|LkSwO\|E{KM7:TR?=	NIXye4dUSU6JRWK=
LU-99A	M1jzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LYWGlEPTB;Mz60O\|ExPSEQvF2=	MXjTRW5ITVJ?
MS-1	Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTNwNUO0Nlkh\|ryP	M{jwS3NCVkeHUh?=
SK-LU-1	Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLTTWM2OD1\|Lke2Nlk2KM7:TR?=	NYLiWWlCW0GQR1XS
SW837	M{HBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLwTWM2OD1\|Lke2N\|M{KM7:TR?=	MVjTRW5ITVJ?
ES8	M3zYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPKVmdKSzVyPUOuPFM5PzdizszN	NHi0PVFUSU6JRWK=
MZ2-MEL	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfXNotKSzVyPUOuPVIxQDZizszN	NUDLc4J4W0GQR1XS
TGW	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnyTWM2OD12LkCxN\|EyKM7:TR?=	M1;MW3NCVkeHUh?=
GP5d	NX31[XBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfFTWM2OD12LkC1N\|YzKM7:TR?=	M3[2OHNCVkeHUh?=
BB49-HNC	M1O3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DxR2lEPTB;ND6xOVIyOyEQvF2=	MXzTRW5ITVJ?
NB13	NFLF[2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfwTWM2OD12LkK2PFg4KM7:TR?=	Moq5V2FPT0WU
NTERA-S-cl-D1	NGT1fVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PJOWlEPTB;ND6yPFYyPSEQvF2=	NGH6VZdUSU6JRWK=
NCI-H1648	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTRwMkm4NVkh\|ryP	MknLV2FPT0WU
LCLC-103H	NHLxS3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDNc4ZMUUN3ME20MlMzOTl3IN88US=>	M{W5dnNCVkeHUh?=
LS-411N	M3OweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTRwNES4PFUh\|ryP	MUfTRW5ITVJ?
NCI-H1092	MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\tTWM2OD12LkS1Olg4KM7:TR?=	NInzNWlUSU6JRWK=
PANC-10-05	NV7aSmJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTKTWM2OD12Lk[5PFQh\|ryP	M3LEOHNCVkeHUh?=
DK-MG	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTRwOEC5N\|Mh\|ryP	MlHuV2FPT0WU
OVCAR-5	NHr4OJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLzTWM2OD12LkixNlI3KM7:TR?=	MmrBV2FPT0WU
CAL-39	M2K0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTRwOEe2O{DPxE1?	Mm\wV2FPT0WU
TE-441-T	NHLPVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TRXmlEPTB;ND65NFU{PyEQvF2=	M2TNSXNCVkeHUh?=
MOLT-16	MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDwb3VKSzVyPUSuPVUzPTNizszN	M4rWXXNCVkeHUh?=
MCF7	Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjGR3poUUN3ME21MlE1PTF5IN88US=>	NHzrdW1USU6JRWK=
CAPAN-1	MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGH6N3pKSzVyPUWuNlU4ODdizszN	NHrW[2FUSU6JRWK=
PSN1	Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTVwMkeyN\|Uh\|ryP	NIjDOlNUSU6JRWK=
NCI-H292	M1H0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvPTWM2OD13LkOwNFQ1KM7:TR?=	MVPTRW5ITVJ?
CPC-N	NG[4eYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTVwM{m0NVkh\|ryP	MVjTRW5ITVJ?
DoTc2-4510	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{O2UmlEPTB;NT60OVM4OSEQvF2=	NVnCe4pkW0GQR1XS
LB1047-RCC	NEXnZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTVwNUW5N\|Mh\|ryP	NUDMOJRwW0GQR1XS
MHH-ES-1	NHzvNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPETWM2OD13LkW5PVA4KM7:TR?=	MkLxV2FPT0WU
NMC-G1	MmTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\3OFJIUUN3ME21MlcxOjJ5IN88US=>	NYLvTlVpW0GQR1XS
SW1710	NV;nfFU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jmUWlEPTB;NT63OFc2OSEQvF2=	MX7TRW5ITVJ?
YAPC	MkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3nTWM2OD13Lke2NlAyKM7:TR?=	M3r5N3NCVkeHUh?=
22RV1	NHf4OlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXRTWM2OD13LkiwNFE6KM7:TR?=	NIT4NllUSU6JRWK=
COLO-679	NXXxRmdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nRWWlEPTB;NT64PFk1QCEQvF2=	NViyXolnW0GQR1XS
TCCSUP	NFrGUJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITnUWpKSzVyPUWuPVMzPTlizszN	MonLV2FPT0WU
C2BBe1	NGTubFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rXT2lEPTB;NT65N\|k4KM7:TR?=	Mo[4V2FPT0WU
TE-15	NWHac41ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{H0V2lEPTB;Nj6wOlYxPSEQvF2=	M17XSnNCVkeHUh?=
SCLC-21H	NV;Rbo9mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWThfmhGUUN3ME22MlExQDR\|IN88US=>	NH;PeJdUSU6JRWK=
EoL-1-cell	M{[xZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3BTZJKSzVyPU[uNVY2PjNizszN	NHvWNIlUSU6JRWK=
NKM-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHWR\|RKSzVyPU[uNVY4OSEQvF2=	NXnDcXA1W0GQR1XS
NCI-H1304	M4rvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXiNplKSzVyPU[uNlc1OjhizszN	MnTsV2FPT0WU
NB6	MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXzc4ZKSzVyPU[uNlk3OjJizszN	MmPVV2FPT0WU
NALM-6	NVPvWld7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jZemlEPTB;Nj6zN\|I{KM7:TR?=	MWPTRW5ITVJ?
NCI-H522	MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvPTWM2OD14LkOzN\|A3KM7:TR?=	M3rNS3NCVkeHUh?=
MV-4-11	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\WU\|dKSzVyPU[uN\|cxPzlizszN	NYrJPYZOW0GQR1XS
LB2241-RCC	NX;xRotZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\XZmlEPTB;Nj6zPFY3PyEQvF2=	MU\TRW5ITVJ?
NCI-H1417	NWPIdYRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;UTWM2OD14LkSwPFQ4KM7:TR?=	MVfTRW5ITVJ?
HT-1197	NHrndFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTZwNUexNlIh\|ryP	NULD[4FsW0GQR1XS
P30-OHK	MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;ZTWM2OD14Lk[yO\|ch\|ryP	MnP3V2FPT0WU
ALL-PO	NWjEdFJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\vSphKSzVyPU[uO\|E6OTZizszN	M3vYPHNCVkeHUh?=
OVCAR-4	MlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYizclJkUUN3ME22Mlc2PDB3IN88US=>	Mnn5V2FPT0WU
HCC2157	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NISwPZdKSzVyPU[uO\|c1PzVizszN	MomxV2FPT0WU
NCI-H838	M2LFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH61fYRKSzVyPU[uPVY1QSEQvF2=	MVvTRW5ITVJ?
NCI-H1299	NIjPdY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXxclRKSzVyPU[uPVcxQSEQvF2=	MkDWV2FPT0WU
SW954	NVrnc3JxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DNSmlEPTB;Nz6yNFA3QCEQvF2=	MVTTRW5ITVJ?
NCI-H441	NUfpOWVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnoTWM2OD15LkO0NFY2KM7:TR?=	M1vzNXNCVkeHUh?=
SK-MEL-2	M3PvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrCTWM2OD15LkS4N\|c{KM7:TR?=	MlLxV2FPT0WU
KARPAS-45	Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;mTWM2OD15Lk[1PVI6KM7:TR?=	MoS3V2FPT0WU
CAL-54	NHn6To1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDWe5J4UUN3ME23MlgzQTd5IN88US=>	NHHiTodUSU6JRWK=
KYSE-180	M3u5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TZSmlEPTB;Nz64PFk1OSEQvF2=	M{nxdnNCVkeHUh?=
NCI-H187	Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPKcZRKSzVyPUeuPVU6PDdizszN	NEPPZ3RUSU6JRWK=
RT-112	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1n3cGlEPTB;OD6wPVY4PyEQvF2=	NYTxblhiW0GQR1XS
NCI-H1437	NWL0d2VWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7FUWxXUUN3ME24MlA6Pzl3IN88US=>	MVvTRW5ITVJ?
SNU-449	NELZOVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRThwMkiyO\|Ih\|ryP	NX\ZemhSW0GQR1XS
HCC1187	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFiyVYtKSzVyPUiuNlk{QTFizszN	NEjKTI9USU6JRWK=
NCI-H2030	MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3O[GFMUUN3ME24MlM4PzF2IN88US=>	NWDKTlhHW0GQR1XS
HuO-3N1	NInHfYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLSOHlKSzVyPUiuN\|c5PDRizszN	MojSV2FPT0WU
COLO-792	MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zGd2lEPTB;OD60NVUzPyEQvF2=	M4POXHNCVkeHUh?=
MIA-PaCa-2	NHjBU\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYP1[oJZUUN3ME24Mlg2PTB6IN88US=>	MlvWV2FPT0WU
SK-N-FI	MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXCU\|JKSzVyPUmuNFQzPSEQvF2=	MnfCV2FPT0WU
MMAC-SF	NV\jW29sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWL4dGhpUUN3ME25MlA6PzVzIN88US=>	M3\UXnNCVkeHUh?=
NCI-H28	NH\ITmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkP4TWM2OD17LkGwOFY6KM7:TR?=	NI[5TGpUSU6JRWK=
ETK-1	M4TRPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPMTWM2OD17LkK5PVc1KM7:TR?=	MUHTRW5ITVJ?
NCI-H1993	MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTlwNESyOlEh\|ryP	MWDTRW5ITVJ?
no-11	M2C3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4ThNWlEPTB;OT60O\|EzKM7:TR?=	MX7TRW5ITVJ?
ChaGo-K-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrHWHFxUUN3ME25MlUyPTh\|IN88US=>	NXTrSoxkW0GQR1XS
NCCIT	NGfrd5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnmeINKSzVyPUmuOVMyPjlizszN	NIjmXodUSU6JRWK=
SAS	NWTkXWVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fjeGlEPTB;MUCuNlQ5KM7:TR?=	NU\FPJZ7W0GQR1XS
A673	MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTFyLkO3NFQh\|ryP	Ml\qV2FPT0WU
NCI-H1522	MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTFyLkO3NFch\|ryP	MnnPV2FPT0WU
NCI-H810	M2XKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\vNFZVUUN3ME2xNE4{QTB5IN88US=>	Ml\QV2FPT0WU
IST-MES1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXzfIZCUUN3ME2xNE41PTZ2IN88US=>	MWnTRW5ITVJ?
GR-ST	M4Hwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDFUmU2UUN3ME2xNE42ODJ2IN88US=>	MWHTRW5ITVJ?
SUP-T1	NWW1Wlk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nQU2lEPTB;MUCuO\|MyPyEQvF2=	MmmyV2FPT0WU
NB5	NYPqUm1oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vPN2lEPTB;MUCuPVAzOiEQvF2=	NX;CdVN4W0GQR1XS
MZ1-PC	NXLD[FY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFv4e5RKSzVyPUGwMlk2PzFizszN	NGrpVVhUSU6JRWK=
SK-CO-1	M2fiZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\pTWM2OD1zMD65PVMyKM7:TR?=	MWLTRW5ITVJ?
Capan-2	NGXmOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LZOWlEPTB;MUGuN\|E6QCEQvF2=	NWP2XJNyW0GQR1XS
697	NEDOfHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPNZW9IUUN3ME2xNU43PzV5IN88US=>	NGDWfJdUSU6JRWK=
REH	NXvVcHZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vzeWlEPTB;MUGuO\|Q2OSEQvF2=	MVPTRW5ITVJ?
GI-1	NYjw[YtYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWe1[GU5UUN3ME2xNU45PjF3IN88US=>	NE\EWZlUSU6JRWK=
BB65-RCC	M1rj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1T0OmlEPTB;MUKuNFkyPiEQvF2=	NWrtclg6W0GQR1XS
NCI-H1651	MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXoUYhKSzVyPUGyMlI1PzhizszN	MkfzV2FPT0WU
NCI-H1618	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfFT2JKSzVyPUGyMlM6PzZizszN	NITMR2dUSU6JRWK=
NCI-H2081	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPTTWM2OD1zMj62NVQyKM7:TR?=	Mm\VV2FPT0WU
GCIY	MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTF{LkeyNVMh\|ryP	M{jEenNCVkeHUh?=
NY	NXznXG9vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vCdmlEPTB;MUOuNFY1OyEQvF2=	NH3ib4FUSU6JRWK=
PANC-03-27	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\6bGlEPTB;MUOuNFgxPyEQvF2=	M{nwXXNCVkeHUh?=
BHY	NUf2N5dRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY[xN5M1UUN3ME2xN{4zOTJzIN88US=>	M{jzfXNCVkeHUh?=
SK-OV-3	MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrE[I1KSzVyPUGzMlM4PjNizszN	NH7tZ5dUSU6JRWK=
5637	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonMTWM2OD1zMz63O\|U6KM7:TR?=	NIHRV\|JUSU6JRWK=
LC-1F	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjFcm1KSzVyPUG0MlA{PTZizszN	M3rs[HNCVkeHUh?=
SNB75	NEDRR4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fCTWlEPTB;MUSuNFM5OyEQvF2=	NV\SdmFDW0GQR1XS
CHP-212	MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPGTWM2OD1zND6wOFY1KM7:TR?=	NFXjN2JUSU6JRWK=
HT-1376	Mn\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLLN2hzUUN3ME2xOE4yOTJ4IN88US=>	NI\oWmNUSU6JRWK=
MONO-MAC-6	M2L2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTF2LkG1NFIh\|ryP	MXXTRW5ITVJ?
CA46	Ml\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XzXmlEPTB;MUSuNVgzPyEQvF2=	M{nBdnNCVkeHUh?=
SCC-15	NV6yNJdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVn6RW1XUUN3ME2xOE42PTh\|IN88US=>	NIC4VI1USU6JRWK=
ATN-1	MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTF2Lk[2Nlch\|ryP	MVXTRW5ITVJ?
NCI-H2405	NVPabol7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;1dYVKSzVyPUG0MlgyPTdizszN	NIj5[ZBUSU6JRWK=
NCI-H716	MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTF2Lki0PVMh\|ryP	NVW3SI1SW0GQR1XS
SW620	NUjCTZJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHCVYVKSzVyPUG0MlkxOTRizszN	NGjDWYhUSU6JRWK=
NCI-H226	MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTTellKSzVyPUG0MlkxQDVizszN	NF3PfoVUSU6JRWK=
SW962	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PwXWlEPTB;MUSuPVQ{OiEQvF2=	NE[3[3lUSU6JRWK=
KYSE-150	NUjYTlh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXvTHBKSzVyPUG0Mlk2PSEQvF2=	MnXiV2FPT0WU
OCUB-M	NVHKZWhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHLTWM2OD1zND65PFg{KM7:TR?=	M4[1OHNCVkeHUh?=
ES7	M3jYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HhdGlEPTB;MUWuNFk5PCEQvF2=	NGDafJVUSU6JRWK=
SW1463	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVT4OoltUUN3ME2xOU41OjJ\|IN88US=>	MV;TRW5ITVJ?
CAKI-1	NVy4VGhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXXVZA6UUN3ME2xOU42OzR4IN88US=>	NHezXWdUSU6JRWK=
MKN28	M2PVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vq[GlEPTB;MUWuOVQ4QSEQvF2=	MkLvV2FPT0WU
SW13	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrDTWM2OD1zNT62NVgh\|ryP	NFXJcoRUSU6JRWK=
A3-KAW	NWfZWm56T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHn6[ldKSzVyPUG1Mlk3QTdizszN	M2KyUXNCVkeHUh?=
LU-65	NFTEbo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTF3Lkm3Olgh\|ryP	NXPWSW5wW0GQR1XS
Calu-1	NVW3e3lDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFX4Z49KSzVyPUG2MlA{PjhizszN	MoXOV2FPT0WU
ST486	NFrkWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmSwTWM2OD1zNj6wOFMyKM7:TR?=	MV3TRW5ITVJ?
BB30-HNC	MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HPb2lEPTB;MU[uNVI1PiEQvF2=	NIjINGlUSU6JRWK=
EGI-1	NE\kcpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWW0PFd5UUN3ME2xOk41PDZizszN	Mn33V2FPT0WU
SH-4	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml62TWM2OD1zNj60O\|MyKM7:TR?=	NYPsRZRPW0GQR1XS
MN-60	NYPBNI8yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfCW45KSzVyPUG3MlIzQTdizszN	M2q4RnNCVkeHUh?=
MPP-89	M1SxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\HTWM2OD1zNz6yOFU6KM7:TR?=	NWnXfW57W0GQR1XS
A2780	NXuwdXM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXL3U2VNUUN3ME2xO{41OTN7IN88US=>	M3fydXNCVkeHUh?=
Daoy	NGDtUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33B[2lEPTB;MUeuOFY6PSEQvF2=	M4Xoe3NCVkeHUh?=
NCI-H2126	NVzMWGpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzONoE6UUN3ME2xO{41PzdzIN88US=>	Mln1V2FPT0WU
NCI-H1563	NHvHXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknxTWM2OD1zNz60PVE4KM7:TR?=	M3TnTHNCVkeHUh?=
8-MG-BA	NUHTU2xUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnPTWM2OD1zNz62OlQ5KM7:TR?=	NH3mbYtUSU6JRWK=
786-0	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DNOWlEPTB;MUeuPFM2OyEQvF2=	MWHTRW5ITVJ?
AM-38	NUXGNHJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nMTmlEPTB;MUeuPVMxPiEQvF2=	M37GNnNCVkeHUh?=
COLO-824	M4f5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\neGlEPTB;MUiuOFQ{PiEQvF2=	MlvGV2FPT0WU
SK-MEL-30	MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWS1WlJiUUN3ME2xPE42ODh{IN88US=>	MWjTRW5ITVJ?
CESS	MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWP6V3BlUUN3ME2xPE44PjB7IN88US=>	NGn4UoFUSU6JRWK=
BL-70	NEHyN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2O1VWlEPTB;MUiuPFE2PiEQvF2=	MlTUV2FPT0WU
NCI-H2170	NUjKWmlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEC1PFlKSzVyPUG4MlkyPzlizszN	NH7GcZJUSU6JRWK=
HT-3	M2ezfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfz[nJ3UUN3ME2xPE46QDNizszN	NXSyVnF5W0GQR1XS
BOKU	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH:5UoNKSzVyPUG5MlA{QDFizszN	MXzTRW5ITVJ?
HPAF-II	NHq3bmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHHNZRKSzVyPUG5MlMxOTVizszN	M1exXnNCVkeHUh?=
KGN	M37yXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3O3VGlEPTB;MUmuOFc3PSEQvF2=	M{PQU3NCVkeHUh?=
MC-CAR	NUjte2hPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLPTWM2OD1zOT62N\|E{KM7:TR?=	MUfTRW5ITVJ?
BHT-101	MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTF7Lke3O{DPxE1?	MkPLV2FPT0WU
SW1783	NHnPdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHZeZd7UUN3ME2xPU44QDB4IN88US=>	NEjCNodUSU6JRWK=
KP-N-YN	NXjBenE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTJyLkCyOlIh\|ryP	MoXVV2FPT0WU
LU-165	MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTJyLkW1O\|Eh\|ryP	M13icHNCVkeHUh?=
GOTO	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;GTWM2OD1{MD62OFUyKM7:TR?=	NIi3WlFUSU6JRWK=
EFM-19	Mn;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jaXWlEPTB;MkGuNFcyPiEQvF2=	MnP2V2FPT0WU
CTV-1	NXrSUnNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;lTWM2OD1{MT6xNFU1KM7:TR?=	MX3TRW5ITVJ?
HEL	NES3Z2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTJzLkSyNVYh\|ryP	Mn6yV2FPT0WU
SNU-C2B	NWDMfpFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTJzLkSyOkDPxE1?	Mlv0V2FPT0WU
ECC4	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml6yTWM2OD1{MT63NFch\|ryP	NXnYVIpNW0GQR1XS
NEC8	MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDFOYRmUUN3ME2yNU45OzZ6IN88US=>	M1mzb3NCVkeHUh?=
KMOE-2	Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTJzLki5NlEh\|ryP	MoW4V2FPT0WU
NCI-H524	NEj4bXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M374[mlEPTB;MkKuNFgxQCEQvF2=	MmXFV2FPT0WU
WSU-NHL	NIfQVWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTJ{LkG1O\|ch\|ryP	M3f4eXNCVkeHUh?=
SF126	M33oNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmT4TWM2OD1{Mj6yOFY6KM7:TR?=	NXXyfIxpW0GQR1XS
HOP-92	M1XZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTJ{LkOxOlch\|ryP	MkTBV2FPT0WU
CTB-1	MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrN[VVKSzVyPUKyMlQ3PzdizszN	NIfVUJlUSU6JRWK=
KYSE-270	NEH4NoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTJ{LkmzOVch\|ryP	NVy1OXJNW0GQR1XS
SK-MEL-24	M3ToS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTJ\|LkG4O{DPxE1?	Ml\qV2FPT0WU
Calu-3	MoHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2O4NGlEPTB;MkOuNlEzQCEQvF2=	NF\HZXZUSU6JRWK=
GAMG	MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPjUItVUUN3ME2yN{4zOzZ5IN88US=>	NIrBV3VUSU6JRWK=
SW1573	MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTJ\|Lke0NVUh\|ryP	MkmyV2FPT0WU
MHH-NB-11	NX;ENZJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDzTWM2OD1{ND6wNVk1KM7:TR?=	MVfTRW5ITVJ?
TK10	NEHXbnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4O5Z2lEPTB;MkSuOVAyOyEQvF2=	MkC1V2FPT0WU
LB373-MEL-D	NHTqV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4X4e2lEPTB;MkSuOlA3PCEQvF2=	MWnTRW5ITVJ?
KALS-1	NXfVWXo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvyTWM2OD1{ND63N\|I4KM7:TR?=	M17ld3NCVkeHUh?=
HUTU-80	NWjROld6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1G0R2lEPTB;MkWuPFA{OiEQvF2=	NGfLOY1USU6JRWK=
HuP-T3	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTJ4LkG2O\|Qh\|ryP	M3Xn[3NCVkeHUh?=
OE19	NFjtNopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjSZ3BmUUN3ME2yOk4zOTV\|IN88US=>	MnfXV2FPT0WU
J82	NIrJRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXTTWM2OD1{Nj6yOFcyKM7:TR?=	MV7TRW5ITVJ?
DU-4475	NILCTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnjeXJKSzVyPUK2MlM5OTlizszN	NV\tdlJjW0GQR1XS
DMS-53	M2r4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrqNJNKSzVyPUK2MlUyOzhizszN	M1nofnNCVkeHUh?=
COLO-741	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vLXGlEPTB;Mk[uPFM1PCEQvF2=	M1fYNXNCVkeHUh?=
SW48	M3\FW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTJ4Lki4NkDPxE1?	NH7ve4JUSU6JRWK=
IGR-1	NEi0Vm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTJ4LkmzN\|Qh\|ryP	MnO4V2FPT0WU
639-V	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTJ5LkCyOFUh\|ryP	M2TQWXNCVkeHUh?=
LK-2	NEj2eGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUG0T4xWUUN3ME2yO{41OTRzIN88US=>	M1PsUnNCVkeHUh?=
NCI-H2347	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmThTWM2OD1{Nz65Olk6KM7:TR?=	NXW5UmVXW0GQR1XS
NCI-H2228	M1HIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlGzTWM2OD1{OD6wPVA2KM7:TR?=	NFfXN\|ZUSU6JRWK=
LS-123	M1nHN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLPTWM2OD1{OD6xNlYzKM7:TR?=	NGH3ToVUSU6JRWK=
U031	NVnY[FNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3wRplbUUN3ME2yPE4zPTJizszN	MkLYV2FPT0WU
NCI-H1792	MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXaTWM2OD1{OD60O\|IyKM7:TR?=	MWjTRW5ITVJ?
NCI-H2087	M{G2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlv3TWM2OD1{OD63OVUzKM7:TR?=	NGnrRZVUSU6JRWK=
NCI-H2342	NWG1fmd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTJ7LkWyNFgh\|ryP	NI[2bYhUSU6JRWK=
SW626	MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrH[lJlUUN3ME2yPU44PTZizszN	NI\SWnFUSU6JRWK=
LB2518-MEL	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2m5N2lEPTB;MkmuPFE2KM7:TR?=	NUGzbWxbW0GQR1XS
RXF393	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LMSGlEPTB;M{CuNFk2OiEQvF2=	MkXqV2FPT0WU
LC4-1	M2jIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvDTWM2OD1\|MD6zNFkzKM7:TR?=	Mn;KV2FPT0WU
NCI-H1694	NETXTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDleG9KSzVyPUOwMlY3OjRizszN	MkXYV2FPT0WU
K5	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDITWM2OD1\|MD65O\|AzKM7:TR?=	MXrTRW5ITVJ?
HDLM-2	NYOzbHEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITsdY5KSzVyPUOwMlk4OjVizszN	NI\POIZUSU6JRWK=
BCPAP	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;5N3FKSzVyPUOxMlg{PzlizszN	NWq5cW5[W0GQR1XS
BC-3	M4H3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlu5TWM2OD1\|Mj6xOFA{KM7:TR?=	NFfVco1USU6JRWK=
LB996-RCC	MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVq5fpk{UUN3ME2zNk4zOzV6IN88US=>	MknUV2FPT0WU
NCI-H2009	NH3DdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELjd2JKSzVyPUOyMlQ6QDFizszN	NH30UlVUSU6JRWK=
HTC-C3	NGjiNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXu4elZlUUN3ME2zN{44PTF7IN88US=>	M{n5e3NCVkeHUh?=
LAMA-84	NVfP[mxHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fSTWlEPTB;M{SuOFQxPyEQvF2=	Mor3V2FPT0WU
CCRF-CEM	M3;UVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLRcllqUUN3ME2zOE42PzF3IN88US=>	MVPTRW5ITVJ?
AN3-CA	NYPPb2d[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXL4OGJwUUN3ME2zOU4xPTZ6IN88US=>	NWTm[ZBLW0GQR1XS
NCI-H1734	NYTXV\|NKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTN3LkK1OlEh\|ryP	NULHRm1RW0GQR1XS
Ca-Ski	Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;sVFlKSzVyPUO1MlQyODFizszN	Mk\EV2FPT0WU
U-266	M1vVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrZRlBKSzVyPUO1MlYyOTRizszN	NG\vPJJUSU6JRWK=
SBC-5	M4TlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\QU2lEPTB;M{WuO\|c5OSEQvF2=	M{jzVHNCVkeHUh?=
GT3TKB	NIfRUHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTN5LkGxOUDPxE1?	Mn;MV2FPT0WU
MDA-MB-175-VII	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\UTWM2OD1\|Nz6yNlQ5KM7:TR?=	MoLzV2FPT0WU
PFSK-1	NUXUcoxUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zVemlEPTB;M{euNlQ{PSEQvF2=	NFLOfZZUSU6JRWK=
IMR-5	NGfMXoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3P0emlEPTB;M{euNlQ5PyEQvF2=	M{eyc3NCVkeHUh?=
Daudi	MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTvUYVJUUN3ME2zO{4{PTl5IN88US=>	NYWxZllSW0GQR1XS
A498	NFm5fHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrWUGZKSzVyPUO3MlczOThizszN	MlXaV2FPT0WU
SCC-4	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTN5Lke4OFMh\|ryP	NX3wU\|hGW0GQR1XS
COLO-680N	M13URWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUWySVZlUUN3ME2zPE4zQDh3IN88US=>	NYLGcYVxW0GQR1XS
SK-MES-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrEd2xKSzVyPUO4MlMzOTVizszN	M3nXVXNCVkeHUh?=
SR	MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLvZmxKSzVyPUO4MlU1QTVizszN	MmTGV2FPT0WU
LNCaP-Clone-FGC	NHPDXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTN6LkW2N\|ch\|ryP	NE\6b4pUSU6JRWK=
SK-HEP-1	NHfmdWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTN6Lke4NlIh\|ryP	MWHTRW5ITVJ?
BPH-1	M1L6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TJVWlEPTB;M{iuPFMzQSEQvF2=	NFXYVWVUSU6JRWK=
NCI-H1755	MnX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTN7LkW4NVch\|ryP	MnPGV2FPT0WU
LXF-289	NHTrXlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWL1[ld[UUN3ME2zPU45ODh2IN88US=>	MnqyV2FPT0WU
SW1088	NXfjWmc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYf5eld6UUN3ME20NE4zOTB5IN88US=>	MmnoV2FPT0WU
MOLT-4	NYnuO3VbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTRyLkK5NFEh\|ryP	NGq4VIJUSU6JRWK=
AsPC-1	M1u3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEW2PZZKSzVyPUSwMlQ2QDNizszN	M{DpVXNCVkeHUh?=
HOP-62	NXz1PVZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorzTWM2OD12MD62OVY5KM7:TR?=	M{LsdHNCVkeHUh?=
A172	M1Tqd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTrR4RJUUN3ME20NE45PTFzIN88US=>	NUX3TXhyW0GQR1XS
SN12C	MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTRyLkmzPFUh\|ryP	MmjWV2FPT0WU
MDA-MB-231	M3e0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYqze5pqUUN3ME20NE46QDl6IN88US=>	NWjBc5h3W0GQR1XS
RPMI-2650	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\y[I9KSzVyPUSxMlE2QTNizszN	MYHTRW5ITVJ?
KYSE-140	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF[xWVlKSzVyPUSxMlgyOjNizszN	M3P1c3NCVkeHUh?=
KINGS-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXNOoZKSzVyPUSyMlQ3QTdizszN	M2nOWHNCVkeHUh?=
HSC-3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTR{Lk[2OlEh\|ryP	NXG3Nm8yW0GQR1XS
PC-14	MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37afWlEPTB;NEOuNVg5OiEQvF2=	MmXyV2FPT0WU
COR-L105	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3VSm9MUUN3ME20N{43PTB{IN88US=>	MVTTRW5ITVJ?
BE-13	M2jkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTR2LkKzO\|Eh\|ryP	MnWzV2FPT0WU
NCI-H661	M4nyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHH1T2NKSzVyPUS0MlI6PThizszN	M3ntc3NCVkeHUh?=
IST-MEL1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLzTWM2OD12ND6zOVk6KM7:TR?=	MofDV2FPT0WU
HCC1806	NGHWWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrm[lFOUUN3ME20OE42QDd\|IN88US=>	M4j4fHNCVkeHUh?=
COLO-800	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmn6TWM2OD12ND64OFU{KM7:TR?=	M3TUPXNCVkeHUh?=
IST-SL2	M13mRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnKzTWM2OD12NT6xNlQ4KM7:TR?=	NX;DNFR3W0GQR1XS
8305C	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XQVWlEPTB;NEWuN\|A6KM7:TR?=	MX7TRW5ITVJ?
UACC-62	MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmGwTWM2OD12Nj6yPFc2KM7:TR?=	MUHTRW5ITVJ?
COR-L23	NXz6RnRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmO5TWM2OD12Nz6xPVkh\|ryP	M1LpRXNCVkeHUh?=
EFE-184	MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TqbWlEPTB;NEeuN\|g5KM7:TR?=	MVfTRW5ITVJ?
DMS-114	NE\TbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3H2Z2lEPTB;NEeuOFE1QSEQvF2=	Mm\6V2FPT0WU
KYSE-520	NEPRPJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfBVWRKSzVyPUS4MlU{OTVizszN	NXPjVHZCW0GQR1XS
SNG-M	NGm5NmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LrZmlEPTB;NEmuOFM1KM7:TR?=	M3KyVnNCVkeHUh?=
A2058	Mo\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nP[WlEPTB;NEmuOFg5PSEQvF2=	NH70TXRUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; PubMed: 26052929 Mol Carcinog Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells. p-IGF1R / IGF1R / p-mTOR / mTOR ; PubMed: 28440057 Cancer Med Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot. cleaved caspase-3 / cleaved PARP; PubMed: 28440057 Cancer Med Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control. pSrc(Y416) / Src; PubMed: 26515601 Oncotarget A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis. p-STAT3(Y705) / STAT3 ; PubMed: 26041671 Mol Cancer H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days. pS6 / S6; PubMed: 21257723 Clin Cancer Res Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.	26052929 28440057 26515601 26041671 21257723
Immunofluorescence	FoxO1; PubMed: 27535223 J Biol Chem After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min. A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.	27535223
Growth inhibition assay	Cell viability; PubMed: 26136493 Neuro Oncol InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.	26136493

In vivo

OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the V_max is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. ^[1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Protein kinase biochemical assays: Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log₁₀ compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerPro^TM Kinase Selectivity Assay Kit.
Cell Research:^[1]	- Collapse Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells Concentrations: 0.02-0.8 μM Incubation Time: 3 days Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model Dosages: 25 mg / kg and 75 mg / kg Administration: Orally administrated at once-daily oral dose for 14 days (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	84 mg/mL (199.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%ddH2O For best results, use promptly after mixing.	6.25mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Linsitinib (OSI-906) SDF

Molecular Weight	421.49
Formula	C₂₆H₂₃N₅O
CAS No.	867160-71-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02546544	Completed	Drug: Linsitinib	Relapsed Ewing Sarcoma\|Refractory Ewing Sarcoma	University of Oxford\|European Organisation for Research and Treatment of Cancer - EORTC\|European Commission\|Astellas Pharma Inc\|Oxford University Hospitals NHS Trust	March 2014	Phase 2
NCT01672736	Terminated	Drug: ASP7487 Velcade Dexamethasone	Multiple Myeloma	University Health Network Toronto\|Multiple Myeloma Research Consortium\|Astellas Pharma Inc	September 2012	Phase 1\|Phase 2
NCT01529684	Completed	Drug: radio-labeled OSI-906\|Drug: OSI-906	Advanced Solid Tumors\|Pharmacokinetics of 14C-OSI-906	Astellas Pharma Global Development Inc.\|Astellas Pharma Inc	March 19 2012	Phase 1
NCT01221077	Completed	Drug: OSI-906\|Drug: Erlotinib\|Drug: Placebo	NSCLC\|Non Small Cell Lung Cancer	Astellas Pharma Inc	April 8 2011	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?
Answer:
OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Pan IGF-1R Inhibitor

GSK1904529A : Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.
Most Potent IGF-1R Inhibitor

BMS-754807 : IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.
IGF-1R Inhibitor in Clinical Trial

BMS-754807 : Phase II for Breast Cancer.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Related IGF-1R Products

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R). Picropodophyllin (PPP) induces apoptosis with antineoplastic activity.
Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Bemcentinib (R428) ^New

R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 (CS-0117) is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 (GSK 552602A) is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
GSK1904529A

GSK1904529A (GSK 4529) is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
BMS-754807

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Features:Muti-inhibitor of the IGR-1R/IR family.
AG-1024

AG-1024 (Tyrphostin, AGS 200) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

Linsitinib (OSI-906)